Neurodegenerative Disorder Therapeutics Market Report 2026
Global Outlook – By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, Strategies, and Forecast to 2030
Neurodegenerative Disorder Therapeutics Market Overview
• Neurodegenerative Disorder Therapeutics market size has reached to $21.66 billion in 2025 • Expected to grow to $34.13 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Elevated R&D Investments Driving Growth In The Neurodegenerative Disorder Therapeutics Market • Market Trend: Innovative Levodopa-Based Therapies For Parkinson’s Disease Management t • North America was the largest region in 2025 and Middle East is the fastest growing region.What Is Covered Under Neurodegenerative Disorder Therapeutics Market?
Neurodegenerative disorder therapeutics refers to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control. The main drug types of neurodegenerative disorder therapeutics are n- methyl d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various indications include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and other indications that ARE distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
What Is The Neurodegenerative Disorder Therapeutics Market Size and Share 2026?
The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $21.66 billion in 2025 to $23.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising prevalence of neurodegenerative disorders, increasing aging population, limited treatment options, growing awareness about early diagnosis, expansion of hospital and neurology care infrastructure.What Is The Neurodegenerative Disorder Therapeutics Market Growth Forecast?
The neurodegenerative disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $34.13 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to development of gene therapies, advancement in monoclonal antibody treatments, integration of ai-based diagnostics and monitoring, rising investment in clinical research and trials, expansion of personalized medicine and targeted therapeutics. Major trends in the forecast period include increasing adoption of neuroprotective and neurorestorative therapies, rising focus on symptom management and patient-centric care, growth in clinical trials for novel neurodegenerative drugs, expansion of personalized and targeted therapeutic approaches, integration of home care and remote monitoring solutions.
Global Neurodegenerative Disorder Therapeutics Market Segmentation
1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types 2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types 3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Parkinson's Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics 2) By Alzheimer's Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies 3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids 4) By Huntington's Disease: Tetrabenazine, Antipsychotic Medications 5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease TreatmentsWhat Is The Driver Of The Neurodegenerative Disorder Therapeutics Market?
Increasing investment in research and development (R&D) for neurodegenerative disorder therapeutics is expected to propel the growth of the neurodegenerative disorder therapeutics market going forward. Investments in research and development for neurodegenerative disorders are launched by governments and organizations for various compelling reasons, including the increasing prevalence, significant unmet medical needs, economic repercussions, global health initiatives, and more. For instance, in March 2023, according to Government of Canada, a Canada-based federal administration, in 2023, the government of Canada revealed a $38.3 million investment aimed at advancing research into neurodegenerative diseases. Therefore, increasing investment in research and development (R&D) for neurodegenerative disorder therapeutics will continue to drive the growth of the neurodegenerative disorder therapeutics industry in the forecast period.Key Players In The Global Neurodegenerative Disorder Therapeutics Market
Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
This chart is for illustrative purposes; the full report includes a detailed competitor analysis and comprehensive overview of the top 10 companies in the market.
This chart maps companies by product innovation and brand strength, with bubble size indicating relative revenue, helping identify market leaders, challengers, and niche players. This is an illustrative chart; the full report provides a complete and accurate competitive analysis.
Explore how leading companies compare across key metrics in our report Get Report
Global Neurodegenerative Disorder Therapeutics Market Trends and Insights
Major companies operating in the neurodegenerative disorder therapeutics market are focusing on developing innovative treatment options such as prodrug formulations to enhance the bioavailability, efficacy, and safety profile of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically converted into active drugs in the body, allowing for controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for people living with advanced Parkinson’s disease. The therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to reduce motor fluctuations and improve patients’ quality of life. This launch represents a significant advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.What Are Latest Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market?
In March 2024, Bristol Myers Squibb Company, a US-based biopharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. With this acquisition, Bristol Myers Squibb aims to strengthen its neuroscience portfolio, accelerate the development of innovative therapies for neuropsychiatric disorders, and expand its research and commercial capabilities in central nervous system (CNS) treatments. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases.
Regional Insights
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.Need data for a specific geography? Request Regional Data
What Defines the Neurodegenerative Disorder Therapeutics Market?
The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This chart presents market attractiveness based on a quantitative evaluation of growth, competition, strategic alignment, and risk, offering a clear view of opportunity areas for decision-making. This chart is for illustrative purposes; the full report contains the complete analysis.
This chart highlights the Total Addressable Market (TAM) by estimating the maximum revenue opportunity using an assumption-driven approach, supporting strategic planning and opportunity sizing across markets. The chart is illustrative; the full report provides a more comprehensive analysis.
Access full TAM calculations and growth projections in our report Get Report
What Key Data and Analysis Are Included in the Neurodegenerative Disorder Therapeutics Market Report 2026?
The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Neurodegenerative Disorder Therapeutics Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $23.65 billion |
| Revenue Forecast In 2030 | $34.13 billion |
| Growth Rate | CAGR of 9.2% from 2026 to 2030 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2030 |
| Segments Covered | Indication Type, Drug Type, Distribution |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. |
| Key Companies Profiled | Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |